Drug Mixture May Slow Colon Cancer

Article

NEW YORK - A study recently reported in the New England Journal of Medicine found that combining a new drug with the standard ones could more effectively slow end-stage colorectal cancer, slightly prolonging victims' lives.

The drug irinotecan, also known as Camptosar, is already approved by the Food and Drug Administration (FDA) for treating patients with advanced, Stage IV colorectal cancer after standard drugs fail. Led by Dr. Saltz of Memorial Sloan-Kettering Cancer Center, a three-drug combination of irinotecan, fluorouracil, and leucovorin increased average survival to 15 months from 13 months, and the share of patients whose tumors temporarily shrank went to 50% from 28%.

In the current study, 226 patients received fluorouracil and leucovorin, while 231 patients got periodic shots of those two drugs plus irinotecan. For more information visit www.fda.gov.

Recent Videos
Cameron Memorial Community Hospital Series With ICT
Ambassador Deborah L. Birx, MD, senior fellow of the George W. Bush Presidential Center
Cameron Memorial Community Hospital series with ICT  (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT  (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Cameron Memorial Community Hospital series with ICT (Image Credit: CMCH)
Isis Lamphier, MPH, MHA, CIC; Tori Whitacre Martonicz, MA; and Heather Stoltzfus, MPH, RN, CIC, at APIC Conference and Expo 2024 (Photo courtesy of Tori Whitacre Martonicz)
Lindsay K. Weir, MPH, CIC, Lead Infection Preventionist/Infection Preventionist III
•	Rebecca (Bartles) Crapanzano-Sigafoos, DrPH, MPH, CIC, FAPIC (corresponding author), executive director of APIC’s Center for Research, Practice, and Innovation, and lead author of the study.
Related Content